Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Ann Rheum Dis
; 70(12): 2095-102, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-21859692
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Interleucina-1beta
/
Síndromes Periódicas Associadas à Criopirina
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article